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Resequencing Candidate Genes Implicates
Rare Variants in Asthma Susceptibility
Dara G. Torgerson,1,11 Daniel Capurso,1 Rasika A. Mathias,2 Penelope E. Graves,3 Ryan D. Hernandez,4
Terri H. Beaty,5 Eugene R. Bleecker,6 Benjamin A. Raby,7 Deborah A. Meyers,6 Kathleen C. Barnes,2
Scott T. Weiss,7 Fernando D. Martinez,3 Dan L. Nicolae,1,8,9,10 and Carole Ober1,10,*
Common variation in over 100 genes has been implicated in the risk of developing asthma, but the contribution of rare variants to
asthma susceptibility remains largely unexplored. We selected nine genes that showed the strongest signatures of weak purifying selec-
tion from among 53 candidate asthma-associated genes, and we sequenced the coding exons and flanking noncoding regions in 450
asthmatic cases and 515 nonasthmatic controls. We observed an overall excess of p values <0.05 (p ¼ 0.02), and rare variants in four
genes (AGT, DPP10, IKBKAP, and IL12RB1) contributed to asthma susceptibility among African Americans. Rare variants in IL12RB1
were also associated with asthma susceptibility among European Americans, despite the fact that the majority of rare variants in
IL12RB1 were specific to either one of the populations. The combined evidence of association with rare noncoding variants in
IL12RB1 remained significant (p ¼ 3.7 3 104) after correcting for multiple testing. Overall, the contribution of rare variants to asthma
susceptibility was predominantly due to noncoding variants in sequences flanking the exons, although nonsynonymous rare variants in
DPP10 and in IL12RB1 were associated with asthma in African Americans and European Americans, respectively. This study provides
evidence that rare variants contribute to asthma susceptibility. Additional studies are required for testing whether prioritizing genes
for resequencing on the basis of signatures of purifying selection is an efficient means of identifying novel rare variants that contribute
to complex disease.Introduction
Despite the many successes of genome-wide association
studies (GWASs), only a small fraction of the heritability
of common diseases is accounted for by the risk alleles
identified through these studies.1–10 One possible explana-
tion for this ‘‘missing heritability’’ is that the genotyping
platforms typically used for GWASs include mostly
common variants (those with a minor allele frequency
[MAF] >0.05) selected for their ‘‘tagging’’ of larger haplo-
type blocks. This strategy is unlikely to tag most of the
rare variants in the genome. In fact, theoretical modeling
favors a scenario in which most of the genetic risk for
common diseases is due to mildly deleterious mutations
that are maintained at low frequency in the population
by weak purifying (negative) selection.11 Such low-
frequency or rare variants are likely to have larger effects
on disease risk than the common variants detected by
GWASs. To date, however, the relative contributions of
alleles with MAF <5% to the heritability of common
diseases have not been comprehensively surveyed.
A limitation to studies of rare variants is that they require
resequencing of genes in cases and controls (or individuals
selected from the tails of a distribution of quantitative
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and advances in sequencing technologies have now made
it possible to directly evaluate the contribution of rare vari-
ants to the risk of common diseases. A second challenge is
in selecting candidate genes for resequencing or for priori-
tizing the selection of genes identified from genome-wide
studies. One approach has been to select genes underlying
Mendelian forms of common diseases. For example,
Cohen and colleagues resequenced genes containing
mutations that result in Mendelian forms of lipidemias
in subjects sampled from the upper and lower 5% of the
distribution of cholesterol levels.12 In a series of studies
of relatively small samples, rare nonsynonymous polymor-
phisms influencing normal variation in cholesterol levels
were identified in many of these genes.13–15 Although
this strategy might help identify genes harboring rare
variants that increase the risk of disease, either Mendelian
subforms do not exist for many common diseases, or
the causal genetic mutations are unknown. Another
approach is to focus on candidate genes and regions
identified through GWASs. Johansen and colleagues used
this approach to implicate rare variants in four genes iden-
tified through a GWAS of hypertriglyceridemia.16 How-
ever, genes with rare variants that contribute to disease
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sufficient effect sizes to be detected through GWASs. Thus,
additional strategies are required for selecting genes for
resequencing studies so that the genes harboring rare vari-
ants that contribute to common disease risk are more likely
to be identified.
Asthma (MIM 600807) represents an excellent example
of a common disease for which GWASs have identified
common variants that collectively account for a very small
proportion of the total genetic risk1–10 and for which
Mendelian subforms are unknown. Collectively, common
variation in well over 100 genes has been associated with
asthma—either through GWASs, linkage and positional-
cloning studies, or candidate-gene studies—with varying
degrees of replication.17–19 A theoretical framework devel-
oped by Pritchard suggested that genes with molecular
signatures of weak purifying selection are more likely to
harbor an excess of rare or low-frequency variants involved
in a complex disease.11 Weak purifying selection prevents
mildly deleterious mutations from reaching appreciable
frequencies in a population as compared to neutral or
adaptive mutations. For example, genes involved in
Mendelian diseases have proportionally more rare varia-
tion20 and show stronger signatures of purifying selection
at nonsynonymous sites.21
We selected nine candidate asthma-associated genes for
resequencing on the basis of evidence of weak purifying
selection in a genome-wide scan for natural selection in
both European and African Americans.22 Our results
suggest that rare variation contributes to asthma suscepti-
bility in both coding exons and their flanking noncoding
regions. Discovering whether prioritizing genes with evi-
dence of purifying selection is an efficient way to identify
genes with rare variation that contributes to the etiology
of common diseases will require additional studies.Subjects and Methods
Study Subjects
Sequencing of coding exons and their corresponding flanking
regions for the nine genes was performed in a total of 510 asth-
matic cases and 515 nonasthmatic controls. After excluding 60
European American cases whose samples did not meet quality
standards, we ended up with a final study population of 108 cases
and 248 controls of European American descent and 342 cases and
267 controls of African American descent. Subjects included 58
European American children who have mild to moderate asthma
and who participated in the Childhood Asthma Research and
Education (CARE) Network,23 150 African American children
recruited from Johns Hopkins University as part of the Genomic
Research on Asthma in the African Diaspora (GRAAD)4 and from
the University of Chicago as part of the National Heart, Lung,
and Blood Institute (NHLBI)-funded Collaborative Studies on the
Genetics of Asthma (CSGA),24 and 50 European American and
192 African American asthmatic adults recruited fromWake Forest
University and the University of Chicago as part of the CSGA and
the Severe Asthma Research Program (SARP; also funded by the
NHLBI).25 Two hundred forty eight European American and 267
African American controls were recruited from Johns Hopkins274 The American Journal of Human Genetics 90, 273–281, FebruaryUniversity, Wake Forest University, and the University of Chicago.
Controls were 18 years old or older, nonasthmatic, and without
any first-degree relatives with asthma.
CARE included European American asthmatic cases; detailed
descriptions of each trial are available online (see Web Resources).
SARP and CSGA included both African American and European
American cases and controls. Subjects with mild to severe asthma
were recruited from SARP centers and the CSGA, and they met the
American Thoracic Society (ATS) definition of severe persistent
asthma.26 All subjects were characterized according to asthma
severity.25,27 Controls were recruited from the same medical
centers and had no personal or first-degree-relative family history
of asthma.
The GRAAD study consisted of self-reported African American
cases and controls from the Baltimore-Washington, D.C. metro-
politan area. To determine the asthma status of all affected individ-
uals, we had a clinical coordinator administer a standardized
questionnaire based on the asthma criteria set by either the
American Thoracic Society28 or the International Study of Asthma
and Allergy in Childhood (ISAAC).29 Asthma was defined as both
a self-reported history of asthma and as a documented history of
physician-diagnosed asthma (past or current). Controls were like-
wise administered a standardized questionnaire and were deter-
mined to be negative for a history of asthma.
Study protocols were approved by the institutional review
boards at Harvard University, Johns Hopkins University, Wake
Forest University, the University of Arizona, and the University
of Chicago.Selection of Genes
Because we do not know how to identify genes that harbor rare
risk alleles, we decided to cast a wide net and include all genes
that had been even marginally (or weakly) implicated in asthma
risk. We compiled a list of 120 candidate asthma-associated genes,
118 from a literature review17 and an additional two,ORMDL3 and
CHI3L1, that GWASs had recently revealed to be associated with
asthma and an asthma-like quantitative phenotype, respectively,
at the time this study was designed6,30. For sequencing, we ulti-
mately selected nine genes that showed the strongest evidence
of purifying selection at nonsynonymous sites in both European
Americans and African Americans from a genome-wide scan for
natural selection22 (Tables 1 and S1, available online). In brief,
we obtained signatures of natural selection at nonsynonymous
sites by comparing levels of human polymorphism (within-
species variation) to chimpanzee sequence divergence (between-
species variation) to estimate the population-scaled selection
coefficient (g ¼ 2Nes) for each gene. We used an extension of
theMcDonald-Kreitman test and the MKPRF program31to identify
loci showing the strongest signatures of purifying selection, as
indicated by a higher proportion of polymorphism within species
versus divergence between species. We ranked genes on the basis
of the probability that g was <0.5; 53 of the asthma-associated
genes had at least one SNP or fixed difference at nonsynonymous
sites in the 20 European Americans and 15 African Americans22
(sequence data were available for 91 of the 120 genes, and 53 of
these genes matched this criterion and were included in the study)
(Table S1). From these, we selected the top nine genes with the
strongest evidence of purifying selection in both populations for
our resequencing study.
The nine genes selected for sequencing included one gene
(CFTR [MIM 602421]) in which severe mutations cause a10, 2012
Table 1. Estimates of the Probability of Negative Selection and the Population-Scaled Selection Coefficient for Nonsynonymous Sites in
Nine Candidate Asthma-Associated Genes in African Americans and European Americans
Gene Symbol MIM Number Pr[g < 0.5]a (g)b AA Pr[g < 0.5] (g) EA
Adrenergic, beta-2-, receptor, surface ADRB2 109690 0.88 (2.5) 0.88 (2.6)
Angiotensinogen AGT 106150 0.89 (1.3) 0.87 (2.8)
Cystic fibrosis transmembrane Conductance regulator CFTR 602421 0.84 (1.9) 0.96 (3.5)
Chitinase, acidic CHIA 606080 0.89 (2.2) 0.92 (2.7)
Dipeptidyl-peptidase 10 DPP10 608209 0.80 (1.6) 0.89 (2.5)
Inhibitor of kappa light polypeptide gene enhancer in B cells IKBKAP 603722 0.96 (2.6) 0.81 (1.2)
Interleukin 12 receptor, beta 1 IL12RB1 601604 0.84 (2.1) 0.91 (2.9)
Phospholipase A2, group VII PLA2G7 601690 0.88 (2.3) 0.90 (2.6)
Transforming growth factor, beta 1 TGFB1 190180 0.83 (2.4) 0.95 (4.0)
The estimates of the probability of selection and the selection coefficient are available as supplemental data in Torgerson et al.22 Estimates for the complete list
of genes are in Table S1.The following abbreviations are used: EA, European Americans; AA, African Americans.
a Probability of negative selection.
b Population-scaled selection coefficient (g ¼ 2Nes).Mendelian lung disease and in which common variants have been
associated with asthma32 and another gene (DPP10 [MIM
608209]) that was initially discovered in a positional cloning study
in Europeans33 and then subsequently detected in a GWAS on
asthma in African Americans.4 The remaining genes were previ-
ously selected as candidate genes on the basis of their known func-
tions andwere subsequently reported to be associatedwith asthma
in at least one published study.17 All of these genes had an esti-
mated probability of purifying selection at nonsynonymous sites
>80% in both European Americans and African Americans and
fell within the 92nd percentile of >10,000 genes included in
a genome-wide scan for natural selection.22DNA Sequencing
Sanger sequencing (on both the forward and reverse strands),
variant detection, and annotation to coding and noncoding
regions of each gene were performed at the NHLBI-supported
Resequencing and Genotyping (RS&G) Service at the J. Craig
Venter Institute (JCVI). PCR primers were designed to cover all
coding exons with amplicon sizes ranging from 350–800 bp and
with a 100 bp overlap between adjacent amplicons. We compared
all primer sequences to the whole-genome assembly to verify their
uniqueness against pseudogenes and gene families. The coordi-
nates of all amplicons are available in Document S2. Chromato-
grams were base and quality checked with Applied Biosystems
KB Basecaller v1.2 (on a 3730xl sequencer) and TraceTuner with
custom calibration for 3730xl (see Web Resources), and they
were mixed-base-called with in-house custom software. We anno-
tated variants to coding and non-coding regions by using the
Ensemble database v.50 (July 2008). Noncoding regions were
intronic, 50 upstream of the transcription start site, and 30 down-
stream of the transcription stop site.Data Analysis
All variants and subjects passing quality control (QC) at the JCVI
were included in the analysis. Additional QC on each variant
was performed with PLINK,34 including an assessment of call rates
and deviation from the Hardy-Weinberg equilibrium. MAFs of
previously identified variants were compared to the HapMapThe America(phase 2, release 24) CEU (Utah residents with ancestry from
northern and western Europe from the CEPH collection) and
YRI (Yoruba in Ibadan, Nigeria) samples 35 and to pilot data
from the 1,000 Genomes Project.36 We inferred ancestral states
of each variant on the basis of sequence identity to the chim-
panzee by using syntenic net alignments of the human (hg18)
and chimpanzee (PanTro2) genomes downloaded from the
UCSC genome browser.37,38 We created plots of the site-frequency
spectrum by resampling the cases and controls for N ¼ 100
chromosomes across each variant to account for missing data
and uneven sampling. For variants with >1 derived state, the
derived states were pooled and compared to the single ancestral
state.
Statistical analyses were performed with PLINK34 and the R
statistical package. We performed tests for allelic association at
individual variants by using Fisher’s exact test to compare counts
of ancestral versus derived alleles in the cases versus controls. For
variants with >1 derived state, derived states were pooled and
compared to the single ancestral state. Odds ratios (ORs) were
estimated with a shrinkage estimator that we obtained by ap-
plying the standard OR estimator to allele counts modified by
adding 1/239. For the African American sample, we estimated the
local European admixture at each gene by using genotypes
from the Illumina 1M and 650K platforms and the LAMP (Local
Ancestry in adMixed Populations) program.40 Admixture was
modeled under seven generations of admixture with a two-popu-
lation model of 80% ancestry from Africa and 20% ancestry from
Europe. Windows were offset by a factor of 0.2, a cutoff for linkage
was set to 0.1, and a constant recombination rate was set to 108.
We repeated tests for allelic association in the African American
sample by using local ancestry as a covariate, andwe used stratified
tests of association in individuals with andwithout local European
admixture for each gene. Using the C-alpha test, we performed
gene-based tests of association on nonsynonymous, synonymous,
and noncoding variants to investigate the contributions of
rare variants to asthma susceptibility (MAF <5% in cases or
controls).41 We used a total of 50,000 permutations to evaluate
statistical significance by shuffling case and control labels to
maintain haplotypes and patterns of missing data. We used 100
permutations in a similar manner to test for an enrichment ofn Journal of Human Genetics 90, 273–281, February 10, 2012 275
Table 2. Total Number of Sites Resequenced in Nine Candidate Asthma-Associated Genes, Including Percent Coverage of Coding Sites, and
the Total Number of Variants Identified in European Americans and African Americans
Gene
Coding Sites
(% Coverage)
Noncoding
Sites
Total
Sites
Total Variants
(EA/AA)
Novel dbSNPa
(EA/AA)
Novel TGPb
(EA/AA)
Total
Shared
Specific
to EA
Specific
to AA
ADRB2 1,206 (97) 674 1,880 37 (19/30) 19 (8/13) 19 (8/13) 12 7 18
AGT 1,451 (100) 1,624 3,075 69 (20/63) 52 (11/46) 47 (11/41) 14 6 49
DPP10 2,142 (85) 12,228 14,370 221 (98/190) 179 (70/149) 153 (64/123) 67 31 123
CFTR 3,910 (89) 13,318 17,228 178 (87/139) 127 (45/94) 119 (41/86) 48 39 91
CHIA 1,417 (100) 5,326 6,743 115 (53/105) 83 (25/73) 68 (20/58) 43 10 62
IKBKAP 3,760 (95) 16,945 20,705 333 (166/284) 247 (91/201) 228 (82/183) 117 49 167
IL12RB1 1,748 (84) 4,718 6,466 100 (43/86) 65 (23/51) 58 (21/45) 29 14 57
PLA2G7 1,289 (98) 5,728 7,017 117 (51/97) 86 (30/68) 86 (30/68) 31 20 66
TGFB1 1,008 (97) 1,810 2,818 55 (31/47) 45 (25/38) 44 (24/37) 23 8 24
The following abbreviations are used: TGP, 1,000 Genomes Project; EA, European Americans; and AA, African Americans.
a Variants that are absent in dbSNP build 129 (last version prior to the addition of pilot data from the 1,000 Genomes Project).
b Variants that are absent from dbSNP build 129 and the 1,000 Genomes Project pilot data.small p values across all tests performed. We combined p values by
using Fisher’s method across the two populations.
Results
Our study population consisted of 108 cases and 248
controls of European American descent and 342 cases and
267 controls of African American descent. A total of
80,302 base pairs, including 17,931 coding sites and
62,371noncoding sites (50 and30UTRs, introns, 50 upstream
regions, and 30 downstream regions) flanking the coding
exons, were sequenced across the nine genes. The average
coverage of coding sites across all genes was 93%, ranging
from 84% in IL12RB1 (MIM 601604) to 100% in both
AGT (MIM 106150) and CHIA (MIM 606080) (Table 2). A
total of 1,225 variants (303 coding and 922 noncoding)
were detected across all nine genes, and 903 (74%) of these
variants were absent in dbSNP version 129 (the last release
prior to the addition of SNPs identified in the 1,000
Genomes Project).Of these 903 SNPs, 81were subsequently
identified in pilot data from the 1,000 Genomes Project. A
total of 657 variants were unique to the African Americans,
184 variants were unique to the European Americans, and
384 variants were shared in both populations. The number
of variants specific to the cases was 275, and the number of
variants specific to the controls was 285. The majority of
variants were rare (frequency<5%), and there was a higher
proportion of rare variants in the African Americans (83%)
than in the European Americans (71%) (Figure 1). The total
counts of nonsynonymous, synonymous, and noncoding
variants in cases and controls in each population are
shown in Table S2, and the distributions of the number of
rare variants carried at the individual level are shown in
Figures S2 and S3.
No individual variant was significantly associated
with asthma in either European Americans or African276 The American Journal of Human Genetics 90, 273–281, FebruaryAmericans after a Bonferroni correction for 1,225 tests
(p < 4 3 105) (Figures S4 and S5, and see Document
S3). However, in African Americans, there was a trend
toward more rare variants in the asthmatic cases than in
the controls (Figure S6). Population structure in African
Americans might be a confounding factor in genetic tests
of association; however, patterns of local European admix-
ture were not significantly different between cases and
controls for any of the genes (Table S3). Consistent with
this finding, results in the African Americans were
unchanged when we included local ancestry as a covariate
or stratified cases and controls by the presence or absence
of local European admixture (not shown).
We investigated gene-based tests for the potential
involvement of rare variants and asthma susceptibility by
using the C-alpha test,41 which allows for mixed effects
of variants at a single locus (i.e., protective or risk alleles).
Overall, we performed a total of 54 gene-based tests
(9 genes 3 3 site classes 3 2 populations) and expected
to see three or fewer p values <0.05 by chance. However,
seven tests had a p value < 0.05 (Table 3), suggesting that
there were at least four true positive associations in our
data. Furthermore, in 100 random permutations of our
data, only two resulted in seven or more p values <0.05
(permuted p ¼ 0.02), indicating a significant enrichment
of small p values in our data. Assuming that there are
2–3 false-positive results in our data, the pattern of signals
seen in Table 2 implies that we expect rare variants in at
least two genes to be true associations with asthma. Note
that there are two genes (DPP10 and IL12RB1) with
multiple signals, making themmore likely to be truly asso-
ciated.
In African Americans, we observed an association
between rare variants and asthma in four of the nine
genes, including nonsynonymous rare variants in DPP10
(Table 4) (p ¼ 0.023) and noncoding rare variants in AGT10, 2012
Table 3. C-alpha Test41 Results of Gene-Based Tests of Association
between Rare Variants and Asthma Susceptibility
Gene
Nonsynonymous Synonymous Non-Coding
N p value N p value N p value
African Americans
ADRB2 6 0.63 5 0.46 11 0.58
AGT 21 0.060 6 0.46 31 0.038
DPP10 14 0.023 8 0.80 151 0.040
CFTR 23 0.82 5 0.60 91 0.11
CHIA 18 0.88 12 0.73 46 0.74
IKBKAP 23 0.44 20 0.67 186 0.047
IL12RB1 13 0.65 15 0.84 45 0.0015
PLA2G7 7 0.60 4 0.90 72 0.67
TGFB1 4 0.12 7 0.39 34 0.16
All 129 0.41 82 0.95 667 0.0029
European Americans
ADRB2 4 0.32 3 0.32 4 0.86
AGT 6 0.22 2 1.0 7 0.47
DPP10 6 0.47 3 0.074 70 0.56
CFTR 24 0.32 4 0.59 44 0.38
CHIA 5 0.64 3 0.38 15 0.67
IKBKAP 14 0.79 9 0.28 96 0.47
IL12RB1 6 0.034 2 1.0 18 0.022
PLA2G7 3 0.65 1 1.0 37 0.57
TGFB1 2 0.46 2 0.51 24 0.083
All 70 0.73 29 0.24 315 0.35
p values are based on 50,000 permutations and are in bold font for values
<0.05. The seven gene-set combinations showing p < 0.05 represent an
enrichment over the null expectation of no association (p ¼ 0.02 based on
100 permutations). The following abbreviation is used: N, number of rare vari-
ants included in each comparison.
Figure 1. Combined Site-Frequency Spectrum of European
American and African American Cases and Controls
Site-frequency spectrum of 1,225 variants identified through the
resequencing of coding exons and flanking noncoding regions
of nine candidate asthma-associated genes in 450 cases (108
European American and 342 African American) and 515 controls
(248 European American and 267 African American). We re-
sampled a total of 100 chromosomes in each of the European
American and African American cases and controls to account
for missing data and differences in sample size. Derived alleles
were pooled for variants with >2 alleles; we used data from the
chimpanzee to infer ancestral states. Plots for individual genes
are shown in Figure S1.(p ¼ 0.038), DPP10 (p ¼ 0.040), IKBKAP (p ¼ 0.047
[MIM 603722]), and IL12RB1 (p ¼ 0.0015). In European
Americans, we observed an association between rare vari-
ants and asthma in both nonsynonymous (Table 4) and
noncoding variants in IL12RB1 (p ¼ 0.034 and 0.022,
respectively). The combined evidence that noncoding
rare variants in IL12RB1 contribute to the risk of devel-
oping asthma in both African Americans and European
Americans yielded a meta-analysis p value of 3.7 3 104,
which surpasses a more stringent Bonferroni correction
for 27 tests (9 genes 3 3 site classes).Discussion
We resequenced the coding exons and flanking noncoding
regions of nine candidate asthma-associated genes that
showed signatures of weak purifying selection, and we
investigated the contributions of rare variants to asthma
susceptibility. The majority (75%) of variants identified
were absent from dbSNP build 129; however, some (9%)
of themwere present in pilot data from the 1,000 Genomes
Project. No individual rare variant was significantly
associated with asthma after a multiple-testing correc-
tion; this finding is not unexpected, given the low statis-
tical power to detect an association for variants with
MAFs <5% in samples of this size. However, gene-based
tests of association suggested a contribution of rare vari-
ants to asthma susceptibility in four (AGT, DPP10, IKBKAP,
and IL12RB1) of the nine genes studied. Only IL12RB1The Americashowed a significant contribution of rare variants to
asthma susceptibility in European Americans, whereas
four genes were identified in African Americans. However,
because the European American sample was smaller than
the African American sample and European populations
are expected to harbor less rare variation overall than
African populations,42 we cannot rule out that the differ-
ences we observe between these samples are due to differ-
ences in statistical power.
Our original expectation was to discover associations
between rare nonsynonymous variants and asthma risk.
However, we found more evidence of rare noncoding vari-
ants in the regions flanking coding exons. For example,
five of the seven p values <0.05 were due to associations
with rare noncoding variants, and associations with non-
coding variants in IL12RB1 were significantly associated
with asthma in both African Americans and European
Americans. Interestingly, 71% of the rare noncodingn Journal of Human Genetics 90, 273–281, February 10, 2012 277
Table 4. Frequencies of Rare Nonsynonymous Variants inDPP10 in
African American Cases and Controls and in IL12RB1 in European
American Cases and Controls
Position
(hg18) Allelesa
Frequency
in Cases
Frequency
in Controls
DPP10 Chromosome 2 in African Americans
115,636,295 G/t 0.0018 0
116,242,430 A/g 0.090 0.094
116,220,141 G/a 0.040 0.028
115,783,333 A/c 0 0.0019
116,201,862 A/g 0.0015 0
116,213,789 A/c 0.0089 0.0076
116,251,275 G/a 0 0.0019
116,288,939 G/a 0.033 0.0075
116,288,964 T/g 0.013 0.011
116,289,003 T/c 0 0.0019
116,289,012 A/g 0.0030 0.0019
116,289,750 C/t 0.0017 0
116,310,579 G/a 0 0.0020
116,314,867 C/a 0.0030 0
IL12RB1 Chromosome 19 in European Americans
18,041,373 G/a 0 0.0020
18,044,095 C/t 0.019 0.0041
18,031,808 C/t 0.0093 0
18,058,613 C/t 0.0046 0
18,031,874 C/a 0 0.0040
18,044,068 G/a 0 0.0020
a The major allele is capitalized, and the minor allele is lowercase.variants in IL12RB1 were specific to either one of the
populations. Furthermore, nonsynonymous sites on
IL12RB1 were associated with asthma in European Ameri-
cans (p ¼ 0.034) but not in African Americans (p ¼ 0.65).
Therefore, even when susceptibility-associated genes are
shared between the two populations, different sets of
rare variants might contribute to the risk of developing
asthma.
Although we targeted coding exons, the majority of sites
that were resequenced were flanking noncoding sites.
In African Americans, only noncoding rare variants
showed a significant contribution to asthma susceptibility
when pooled across all genes (p ¼ 0.0029), even though
nonsynonymous substitutions are predicted to have
larger effects on disease. Indeed, two genes (DPP10 in
African Americans and IL12RB1 in European Americans)
show evidence of rare nonsynonymous variants that are
involved in asthma susceptibility. However, both of
these genes also showed significant contributions of non-
coding rare variation. Although it is possible that the
most highly penetrant nonsynonymous mutations are278 The American Journal of Human Genetics 90, 273–281, Februarytoo rare to be detected in studies of only hundreds of cases,
our results suggest that rare noncoding variation in regions
flanking exons play a more prominent role in asthma
susceptibility.
There is currently great debate as to whether more of the
heritability of common diseases, such as asthma, is ex-
plained by rare or common variants. Recent GWASs on
asthma have identified common variants that explain
very little of the heritability of asthma—their estimated
effect sizes range from 1.1 to 1.3.1–10 These findings are
consistent with either or both of the following scenarios:
a large number of common variants that individually
confer only a modest increase in the risk of asthma (such
as for height43) and/or a large number of rare variants
with larger effect sizes but which are not well tagged by
commercial genotyping platforms. In the current study,
we find associations between rare variants and asthma
susceptibility in four of the nine genes studied, but we
do not find associations between common variants and
asthma susceptibility in any of the nine genes (see Docu-
ment S3). Ongoing exome-sequencing studies in larger
populations will better illuminate the relative contribu-
tions of rare and/or common variants to the heritability
of asthma, but such studies might neglect the majority of
noncoding variants. Our results suggest that noncoding
variants in the exon-flanking sequences should not be
ignored in future sequencing studies.
On the basis of theoretical predictions11 and because
Mendelian-disease-associated genes have a greater propor-
tion of rare variants20 and show strong signatures of
purifying selection compared to other genes,21 we hypo-
thesized that complex-disease genes harboring rare vari-
ants with larger effect sizes might show similar evolu-
tionary patterns. We therefore selected candidate genes
for this study on the basis of their evidence of weak puri-
fying selection, and we identified significant associations
between rare variants and asthma in up to four of the
nine genes selected (Table S1). Future resequencing
studies will illuminate whether selecting candidate genes
on the basis of evidence of purifying selection increases
the chances of finding genes harboring rare variants
contributing to disease risk or whether we could have
achieved similar results by selecting nine candidate
asthma-associated genes at random from the list of 53.
Lastly, regardless of whether there is a direct relationship
between natural selection and asthma susceptibility, genes
subjected to purifying selection might be more relevant
in a broader range of processes and might therefore harbor
a greater proportion of rare variation with functional
effects.11
Overall, our results suggest that rare variants play an
important role in asthma susceptibility in both African
Americans and European Americans and that multiple
rare variants at a single locus can contribute to a common
disease etiology. Additional studies will need to address
whether using signatures of purifying selection to priori-
tize candidate genes for resequencing studies or to assign10, 2012
weights to genes in exome-sequencing studies is an effec-
tive way of identifying novel rare variants that contribute
to a common disease.Supplemental Data
Supplemental Data include six figures, three tables, and two data
files and can be found with this article online at http://www.cell.
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